New IL-18/IL-1F4 Proteins from R&D Systems

Our Recombinant Human and Mouse IL-18/IL-1F4 proteins are manufactured in-house and offer a much better value than the closest competitor. Compare quantity, units, purity, endotoxin levels, and dollars per unit for yourself using the table below.

IL-18/IL-1F4 Protein Benefits Include:

  R&D Systems
(Catalog # 9124-IL)
Leading Competitor R&D Systems
(Catalog # 9139-IL)
Leading Competitor
Species Human Human Mouse Mouse
Source E. coli E. coli E. coli E. coli
Mass per vial 10 µg 50 µg 500 µg 25 µg 200 µg 10 µg 50 µg 500 µg 25 µg 200 µg
Activity (ED50) 1.5-9 ng/mL 1.5-9 ng/mL 0.06-0.36 ng/mL 0.06-0.36 ng/mL
Endotoxin
specification
<0.1 per 1 µg of the protein by the LAL method. <1.0 per 1 µg of the protein by the LAL method. <0.1 per 1 µg of the protein by the LAL method. <1.0 per 1 µg of the protein by the LAL method.
Purity >95% by SDS-PAGE (Silver Staining and Coomassie) >90% by SDS-PAGE (Coomassie) >90% by SDS-PAGE (Silver Staining and Coomassie) >90& by SDS-PAGE (Coomassie)
Price $169 $289 $1,229 $349 $1,439 $169 $289 $1,229 $349 $1,439
Dollars per µg $16.90 $5.78 $2.46 $13.96 $7.20 $16.90 $5.78 $2.46 $13.96 $7.20

Get the most superior IL-18 on the market.

Buy rhIL-18 Now Buy rmIL-18 Now

Compare IL-18/IL-1F4 Protein Bioactivity

Recombinant human IL-18 protein bioactivity Recombinant human IL-18 protein bioactivity

A) Recombinant Human IL-18 (Catalog # 9124-IL) induces IFN-gamma secretion by KG-1 human acute myelogenous leukemia cells. The ED50 for this effect is typically 1.5-9 ng/mL. IFN-gamma was measured in the cell culture supernatant using the Human IFN-gamma Quantikine® ELISA kit (Catalog # DIF50). B) Recombinant Mouse IL-18/IL1F4 (Catalog # 9139-IL) induces IFN-gamma secretion by activated mouse T cells. The ED50 for this effect is typically 0.06-0.36 ng/mL. IFN-gamma was measured in the cell culture supernatant using the Mouse IFN-gamma Quantikine® ELISA kit (Catalog # MIF00). The combination of high activity and competitive pricing makes R&D Systems® IL-18 proteins the better choice.

Increased IL-18/IL-1F4 Protein Stability

Recombinant mouse IL-18 protein stability

Recombinant Mouse IL-18/IL-1F4 (Catalog # 9139-IL) induces IFN-gamma secretion by activated mouse T cells. Serial dilutions of either R&D Systems® IL-18 or IL-18 from a leading competitor (vials freshly reconstituted or vials stored 1 month at 4 °C after reconstitution) were incubated overnight with activated mouse T cells. IFN-gamma was measured in the cell culture supernatant using the Mouse IFN-gamma Quantikine® ELISA kit (Catalog # MIF00).

Our IL-18/IL-1F4 Proteins Provide Superior Purity

Recombinant human IL-18 protein purity
Recombinant Human IL-18/IL-1F4(ng/mL)
Recombinant human IL-18 protein purity
Recombinant Mouse IL-18/IL-18-1F4(ng/mL)

1 µg/lane of Recombinant Human IL-18/IL-1F4 (Catalog # 9124-IL) (A) and Recombinant Mouse IL-18/IL-1F4 (Catalog # 9139-IL) (B) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing a single band at 18 kDa.

Background Information for IL-18

Interleukin-18 (IL-18), a member of the IL-1 family of pro-inflammatory cytokines, is produced by various hematopoietic and nonhematopoietic cells, including dendritic cells, macrophages, microglial cells, keratinocytes, and epithelial cells (1, 2). IL-18 is expressed as a 24 kDa inactive precursor (pro-IL-18) and processed by the intracellular cysteine protease caspase-1 into a 17.2 kDa active mature molecule and released from cells (3, 4). IL-18 plays important roles regulating both innate and acquired immune responses through its effects on natural killer cells, monocytes, dendritic cells, T cells, and B cells. It is a target for immune intervention in infectious diseases, autoimmune diseases, and cancers (5-7).

Get the most superior IL-18 on the market.

Buy rhIL-18 Now Buy rmIL-18 Now

References

  1. Okamura, H. et al. (1995) Nature 378:88.
  2. Gracie, J.A. et al. (2003) J. Leukoc. Biol. 73:213.
  3. Dinarello, C.A. et al. (2013). Front. Immunol. 4:289.
  4. Wei, H. et al. (2014) FEBS Lett. 558:3838.
  5. Wawrocki, S. et al. (2016) Acta. Biochim. Pol. 63:59.
  6. Kanai, T. et al. (2013) Curr. Drug Targets 14:1392.
  7. Fabbi, M. et al. (2015) J. Leukoc. Biol. 97:665.